StockNews.AI
HIMS
StockNews.AI
3 days

Hims & Hers (HIMS) Stock Lawsuits: Investors Urged to Act - Hagens Berman

1. Hims & Hers faces a class-action lawsuit over misleading statements made to investors. 2. Stock plummeted over 34% after Novo Nordisk canceled its partnership with Hims. 3. FTC is investigating Hims over advertising and subscription cancellation practices. 4. Hagens Berman urges affected investors to submit their claims before Aug. 25, 2025. 5. The lawsuit reveals significant issues regarding Hims' business practices and sustainability.

6m saved
Insight
Article

FAQ

Why Very Bearish?

The abrupt termination of the partnership and subsequent lawsuit indicate severe operational issues similar to past market reactions to legal troubles faced by companies like Valeant Pharmaceuticals, which suffered a stock crash post allegations of fraud.

How important is it?

The class-action lawsuit could significantly impact Hims' market position and investor trust, resulting in stock devaluation. Similarly, previous legal challenges faced by health and pharmaceutical sectors create precedent for investor pessimism.

Why Short Term?

Immediate investor reaction to legal actions and stock price volatility due typically results from quick news cycles, as seen with companies facing sudden litigation like Tesla in 2018, which saw immediate price drops.

Related Companies

NVDAPFEAMGN
SAN FRANCISCO, Aug. 20, 2025 (GLOBE NEWSWIRE) -- Investors who lost money in Hims & Hers (NYSE: HIMS) are being urged to actively participate in a securities class action lawsuit. The lawsuit alleges that Hims made misleading statements about its GLP-1 weight-loss drug business and its partnership with Novo Nordisk, which was abruptly canceled. This comes after Hims stock plummeted by over 34% on June 23, 2025, when Novo Nordisk ended the collaboration, citing Hims’ “deceptive promotion and selling of illegitimate, knockoff versions of Wegovy®.” If you suffered substantial losses, you may have the opportunity to serve as Lead Plaintiff. The deadline to apply is August 25, 2025. Hagens Berman urges Hims & Hers investors to submit your losses now. Class Period: Apr. 29, 2025 – June 23, 2025Lead Plaintiff Deadline: Aug. 25, 2025Visit: www.hbsslaw.com/investor-fraud/hims Contact the Firm Now: HIMS@hbsslaw.com844-916-0895 The Lawsuit Against Hims & Hers Class-action lawsuits are underway against Hims & Hers Health Inc., representing investors who bought or acquired company securities between April 29, 2025, and June 23, 2025. The lawsuit alleges that Hims & Hers and its top executives violated the Securities Exchange Act of 1934 by making false and misleading statements to investors. Allegations of Misconduct The core of the legal action revolves around Hims & Hers’ partnership with Novo Nordisk. The lawsuit claims the company was deceptively promoting and selling "illegitimate, knockoff versions of Wegovy®." According to the complaint, Hims & Hers failed to disclose that this practice put patient safety at risk and could lead to the termination of the lucrative Novo Nordisk collaboration. The Aftermath of the Partnership’s Collapse On June 23, 2025, the alleged misrepresentations came to light when Novo Nordisk announced it was ending its partnership with Hims & Hers. The pharmaceutical company explicitly cited Hims & Hers’ “deceptive promotion and selling” of unauthorized versions of Wegovy® as the reason. This news caused Hims & Hers' stock to plummet by over 34%. In a separate development, Bloomberg News reported on August 14 that the Federal Trade Commission (FTC) is now investigating Hims & Hers over its advertising and subscription cancellation practices. Hagens Berman Investigates Investor Claims Hagens Berman, a national plaintiffs’ rights law firm, is investigating whether Hims & Hers may have misled investors about its business practices, particularly concerning its compounded weight-loss drugs and the terminated Novo Nordisk partnership. Reed Kathrein, the Hagens Berman partner leading the investigation, commented on the situation, “This isn’t just about a failed partnership; it’s about whether the company's business model was sustainable and properly represented to the market in the first place. The swift termination of the Novo Nordisk deal and the subsequent stock price collapse suggest there may have been a fundamental disconnect between what investors were told and the underlying reality of Hims' operations.” If you invested in Hims & Hers and have substantial losses, or have knowledge that may assist the firm’s investigation, submit your losses now » If you’d like more information and answers to frequently asked questions about the Hims & Hers case and our investigation, read more » Whistleblowers: Persons with non-public information regarding Hims & Hers should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at 844-916-0895 or email HIMS@hbsslaw.com. About Hagens BermanHagens Berman is a global plaintiffs’ rights complex litigation firm focusing on corporate accountability. The firm is home to a robust practice and represents investors as well as whistleblowers, workers, consumers and others in cases achieving real results for those harmed by corporate negligence and other wrongdoings. Hagens Berman’s team has secured more than $2.9 billion in this area of law. More about the firm and its successes can be found at hbsslaw.com. Follow the firm for updates and news at @ClassActionLaw.  Contact: Reed Kathrein, 844-916-0895

Related News